

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION

Inventor(s): CHOO et al.

Appln. No.: 09

Series Code ↑

646,353

Serial No. ↑

Filed: September 18, 2000

Hon. Commissioner of Patents

Washington, D.C. 20231

Group: 533R

Examiner:

Atty. Dkt.

unknown


273884

P00428US

M#

Client Ref

Appln. Title: NUCLEIC ACID BINDING PROTEINS



Sir:

REPLY/AMENDMENT/LETTER

Date: August 13, 2001


This is a reply/amendment/letter in the above-identified application and includes the herewith attachment of same date and subject which is incorporated hereinto by reference and the signature below is treated as the signature to the attachment in absence of a signature thereto.

FEE REQUIREMENTS FOR CLAIMS AS AMENDED

1. Small Entity claim A. <input type="checkbox"/> NOT made B. <input type="checkbox"/> Withdrawn C. <input type="checkbox"/> made herewith D. <input checked="" type="checkbox"/> made previously		For B & C See Required Separate Paper (Pat-256)		Claims remaining after amendment	Highest number previously paid for	Present Extra	Large/Small Entity
2. Total Effective Claims		29	**minus	29	0	x \$18/\$9 =	
3. Independent Claims		4	***minus	4	0	x \$80/\$40 =	
4. If amendment enters proper multiple dependent claim(s) into this application for first time (leave blank if this is a reissue application) add							+ \$270/\$135 =
5. Original due Date: July 23, 2001		<input type="checkbox"/> NONE					
6. Petition is hereby made to extend the original due date to cover the date this response is filed for which the requisite fee is attached		(1 mo)	\$110/\$55 =			+ \$55	
		(2 mos)	\$390/\$195 =				
		(3 mos)	\$890/\$445 =				
		(Usable only for ≤ 2mo.OA --- 4 mos)	\$1390/\$695 =				
		(Usable only for 30 day/1mo.OA --- 5 mos)	\$1890/\$945 =				
7. Enter any previous extension fee paid since above original due date and subtract						- \$0	
8.						Extension Fee Attached	
9. If Terminal Disclaimer attached, add Rule 20(d) official fee						+ \$110/\$55	
10. If IDS attached requires Official Fee under Rule 97 (c), add						+ \$180	
or if Rule 97(d) Request add						+ \$180	
11. After-Final Request Fee per rules 129(a) and 17(r)						+ \$710/355	
12. No. of additional inventions for examination per Rule 129(b).....						x \$710/355 ea	
13. Request for Continued Examination (RCE)						+ \$710/355	
14. Petition fee for						+ \$0	
15.						TOTAL FEE ENCLOSED =	
						\$55	

DATE:

DISK TO STIC



16. *If the entry in this space is less than entry in next space, the "Present Extra" result is "0".

17. **If the "Highest number previously paid for" in this space is less than 20, write "20" in this space.

18. ***If the "Highest number previously paid for" in this space is less than 3, write "3" in this space.

08/15/2001 UEDUVIJE 00000082 09646353

01 FD:215

55.00 OP

Our Deposit Account No. 03-3975)

(Our Order No. 71278 273884

C#

M#

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficiencies only) now or hereafter relative to this application and the resulting Official Document under Rule 20, or credit any overpayment, to our Accounting/Order Nos. shown above, for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal sheet is filed.

Query: Is appeal deadline now? If so, file Notice of Appeals separately.

Pillsbury Winthrop LLP
Intellectual Property Group

By Atty: Blair E. Taylor

Sig:

Reg. No. 44370

1600 Tysons Boulevard

McLean, VA 22102

Tel: (703) 905-2000

Atty/Sec: BET/LMR


Fax: (703) 905-2500

Tel: (703) 905-2198

PTO/PCT Rec'd 18 AUG 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of
CHOO et al.



Group Art Unit: not assigned

Application No.: 09/646,353

Examiner: not assigned

Filed: September 18, 2000

FOR: NUCLEIC ACID BINDING PROTEINS

* * * * *

August 13, 2001

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS

Hon. Commissioner of Patents
Washington, D.C. 20231

Sir:


Responsive to the communication mailed May 23, 2001, Applicants submit herewith a Sequence Listing in compliance with 37 C.F.R. §§1.821-1.825. Both a paper version of the Sequence Listing and a computer readable format containing the same information as the paper version of the Sequence Listing are enclosed, together with a statement of support. Because the Sequence Listing was prepared from sequences existing in the application as filed, the Sequence Listing will not introduce new matter into the application. Entry and consideration are respectfully requested.

CHOO et al. - Application No. 09/646,353

Applicants respectfully submit that the application is in condition for allowance. Notification to that effect is earnestly solicited. Should questions regarding patentability arise, the Examiner is invited to telephone the undersigned to discuss the same.

Respectfully submitted,

PILLSBURY WINTHROP LLP

By: 
Blair Elizabeth Taylor, Ph.D.
Reg. No. 44,370
Tel. No.: (703) 905-2198
Fax No.: (703) 905-2500

1600 Tysons Boulevard
McLean, Virginia 22102
(703) 905-2000



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NO	FIRST NAMED APPLICANT	ATTY. DOCKET NO
09/646353	CHOO	Y PM273884
INTERNATIONAL APPLICATION NO		
PCT/GB99/00816		
I.A. FILING DATE	PRIORITY DATE	
17 MAR 99	17 SEP 00	
DATE MAILED		

23 MAY 2001

PILLSBURY MADISON & SUTRO
NINTH FLOOR
1100 NEW YORK AVENUE NW
WASHINGTON, DC 20005 3918**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ☒ The application fails to comply with the requirements of 37 CFR 1.821-1.825.
- ☒ This application does not contain, a "Sequence Listing" as a separate part of the disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
- ☐ A copy of the "Sequence Listing" in computer readable format has not been submitted as required by 37 CFR 1.821(e).
- ☐ A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ The paper copy or compact disc of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ Other: _____

**APPLICANT MUST PROVIDE:**

- ☒ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- ☐ An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
CALL:

(703) 308-4216, for Rules interpretation,
(703) 308-4212, for CRF submission help,
(703) 287-0200, for PatentIn software help.

Paulette Kidwell, Paralegal
Telephone: 703-305-3656

FORM PCT/DO/EO/920 (March 2001)